Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPNT message board posts where the ticker symbol OPNT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPNT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-13-002597 (34 Act)  Size: 46 KB
2013-02-11 005-60291
13589481
15-12G  Documents Securities registration termination [Section 12(g)]
Acc-no: 0001193125-12-518791 (34 Act)  Size: 11 KB
2012-12-31 000-30931
121292416
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069989 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290185
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069987 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290178
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278392
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278391
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058920 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058763 Size: 15 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058762 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058761 Size: 8 KB
2012-12-20
More OPNT SEC Filings


Related news from
Thu, 22 Feb 2018
13:00:00 +0000
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
SAN DIEGO, Feb. 22, 2018-- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple opioid blockers such ...
Tue, 13 Feb 2018
17:00:00 +0000
OPNT: Developing Longer-Acting Opioid Overdose Treatment
On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.
Mon, 12 Feb 2018
13:00:00 +0000
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Based on FDA Feedback, Opiant Intends to Pursue 505 Development Pathway. Opiant Anticipates Submitting an NDA for this Product Candidate in 2020. SANTA MONICA, Calif., Feb. 12, 2018-- Opiant Pharmaceuticals, ...
Thu, 08 Feb 2018
13:00:00 +0000
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
SANTA MONICA, Calif., Feb. 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will record a total ...
Thu, 01 Feb 2018
12:40:00 +0000
Report: Exploring Fundamental Drivers Behind Bryn Mawr Bank, Utah Medical Products, Opiant Pharmaceuticals, Whiting Petroleum, International Business Machines, and QUALCOMM — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bryn ...
Tue, 02 Jan 2018
21:01:00 +0000
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants
SANTA MONICA, Calif., Jan. 02, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the receipt of approximately ...
Sun, 31 Dec 2017
18:45:23 +0000
Insider Q&A: Narcan exec talks merits of spray for overdoses
Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...
Wed, 20 Dec 2017
19:30:00 +0000
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.
Wed, 20 Dec 2017
13:00:00 +0000
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward. SANTA MONICA, Calif., Dec. 20, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company ...
Tue, 19 Dec 2017
15:30:00 +0000
OPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal Spray
On December 13, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the first quarter of fiscal year (FY) 2018 that ended Oct. 31, 2017. The U.S. continues to battle an opioid crisis nationwide.
Tue, 19 Dec 2017
15:00:00 +0000
Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell
What: Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Roger ...
Tue, 19 Dec 2017
13:00:00 +0000
Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017
SANTA MONICA, Calif., Dec. 19, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will ring the Nasdaq ...
Mon, 18 Dec 2017
13:00:00 +0000
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
Data Published Online in Journal of Medicinal Chemistry. Company Evaluating Potential Clinical Program for OPNT005. SANTA MONICA, Calif., Dec. 18, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical ...
Thu, 07 Dec 2017
15:26:32 +0000
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
Categories: Yahoo FinanceGet free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more <b>(Read more...)</b>
Mon, 04 Dec 2017
21:05:00 +0000
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
SANTA MONICA, Calif., Dec. 04, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal ...
Mon, 16 Oct 2017
19:00:00 +0000
OPNT: Looking to Keep Momentum Going into Fiscal 2018
Opiant Pharmaceuticals, Inc. (OPNT) is a specialty pharmaceutical company developing treatments for substance use, eating disorders, and addiction disorders based on the company’s expertise in opioid receptor antagonists. Opiant currently has one FDA approved drug, NARCAN® Nasal Spray, which is marketed by Adapt Pharmaceuticals through an exclusive collaboration. Fiscal 2017 was a transformative year for Opiant, as the company monetized the royalties for NARCAN® Nasal Spray, uplisted to the Nasdaq stock exchange, strengthened the leadership team with the appointment of a new Chief Financial Officer, and announced encouraging Phase 1 data for OPNT002 in Alcohol Use Disorder (AUD).
Fri, 13 Oct 2017
23:17:29 +0000
Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) trades with a trailing P/E of 12.4x, which is lower than the industry average of 23.5x. While this makes OPNT appear like a great stock toRead More...
Wed, 04 Oct 2017
11:20:00 +0000
Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ), following which we have ...
Mon, 02 Oct 2017
11:00:00 +0000
Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Opiant Pharmaceuticals, Inc. (OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan's proprietary ProNeura™ sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic levels of an opioid antagonist, continuously for up to 6 months, may be ideally suited for the prevention of opioid relapse and overdose.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has been the most valuable tool I have ever come across when it comes to managing my investments. I can honestly say that the information shared on ValueForum has led me to retire earlier than expected. This is a wonderful investment site, period." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards